Propel Bio Management »

Heron Therapeutics shares owned by Propel Bio Management

Quarter-by-quarter ownership of Heron Therapeutics (HRTX) shares owned by Propel Bio Management from 13F filings

Historical chart of Propel Bio Management investment in Heron Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Heron Therapeutics held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Heron Therapeutics by Propel Bio Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $177k 104k 1.70

More positions owned by Propel Bio Management

Plains Gp Holdings Lp-cl Comm (PAGP)
Applied Therapeutics Comm (APLT)
Tscan Therapeutics Comm (TCRX)
Madrigal Pharmaceuticals Comm (MDGL)
Crinetics Pharmaceuticals In Comm (CRNX)
Fulcrum Therapeutics Comm (FULC)
Fidelity Inv Mmtrsy 1 680 Comm
Phathom Pharmaceuticals Comm (PHAT)
Day One Biopharmaceuticals I Comm (DAWN)
Ardelyx Comm (ARDX)
Athira Pharma Comm (ATHA)
Telesat Corp Comm (TSAT)
Simplify Enhanced Income Comm (HIGH)
Akero Therapeutics Comm (AKRO)
Vanguard Short-term Bond Comm (BSV)

View all positions for Propel Bio Management

Top funds holding Heron Therapeutics

Vanguard Group
Franklin Resources
Clearline Capital
OrbiMed Advisors
Tejara Capital
Palisade Capital Management
JW Asset Management
Orchard Capital Managment
Monaco Asset Management SAM
Tang Capital Management
Congress Park Capital
D. E. Shaw & Co
Millennium Management
New York State Common Retirement Fund
Charles Schwab Investment Management

View all funds holding Heron Therapeutics